Camilla Recordati1,2, Marcella De Maglie3,4, Claudia Cella4,5, Simona Argentiere4,5, Saverio Paltrinieri3, Silvia Bianchessi4, Marco Losa4, Fabio Fiordaliso6, Alessandro Corbelli6, Gianpaolo Milite7, Federica Aureli8, Marilena D'Amato8, Andrea Raggi8, Francesco Cubadda8, Sabina Soldati4, Cristina Lenardi4,5,9, Eugenio Scanziani3,4. 1. Dipartimento di Medicina Veterinaria (DIMEVET), Università degli Studi di Milano, 26900, Lodi, Italy. camilla.recordati@unimi.it. 2. Fondazione Unimi, 20139, Milan, Italy. camilla.recordati@unimi.it. 3. Dipartimento di Medicina Veterinaria (DIMEVET), Università degli Studi di Milano, 26900, Lodi, Italy. 4. Fondazione Unimi, 20139, Milan, Italy. 5. Dipartimento di Fisica, Università degli Studi di Milano, 20133, Milan, Italy. 6. Unit of Bio-imaging, Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy. 7. Scientific Consultant, Udine, Italy. 8. Istituto Superiore di Sanità - National Institute of Health, 00161, Rome, Italy. 9. Centro Interdisciplinare Materiali e Interfacce Nanostrutturati (CIMAINA), Università degli Studi di Milano, 20133, Milan, Italy.
Abstract
BACKGROUND: Widespread use of silver in its different forms raises concerns about potential adverse effects after ingestion, the main exposure route for humans. The aim of this study was to investigate in CD-1 (ICR) male mice the tissue distribution and in vivo effects of 4-week oral exposure to 0.25 and 1 mg Ag/kg bw 10 nm citrate coated silver nanoparticles (AgNPs) and 1 mg Ag/kg bw silver acetate (AgAc) at the end of treatment (EoT) and after 4 weeks of recovery. RESULTS: There were no treatment-related clinical signs and mortality, and no significant effects on body and organ weights at the EoT and after recovery. Treatment-related changes in hematology and clinical chemistry were found after recovery, the most relevant being a dose-dependent lymphopenia and increased triglycerides in AgNP-treated mice, and increased levels of urea in all treated groups, associated with decreased albumin only in AgAc-treated mice. At the EoT the highest silver concentration determined by Triple Quadrupole ICP-MS analysis was found in the brain, followed by testis, liver, and spleen; much lower concentrations were present in the small intestine and kidney. Tissue silver concentrations were slightly higher after exposure to AgAc than AgNPs and dose dependent for AgNPs. After recovery silver was still present in the brain and testis, highlighting slow elimination. No histopathological changes and absence of silver staining by autometallography were observed in the organs of treated mice. At the EoT GFAP (astrocytes) immunoreactivity was significantly increased in the hippocampus of AgNP-treated mice in a dose-dependent manner and Iba1 (microglial cells) immunoreactivity was significantly increased in the cortex of 1 mg/kg bw AgNP-treated mice. After recovery, a significant reduction of Iba1 was observed in the cortex of all treated groups. TEM analysis of the hippocampus revealed splitting of basement membrane of the capillaries and swelling of astrocytic perivascular end-feet in 1 mg/kg bw AgNP- and AgAc-treated mice at the EoT. CONCLUSIONS: Our study revealed accumulation and slow clearance of silver in the brain after oral administration of 10 nm AgNPs and AgAc at low doses in mice, associated with effects on glial cells and ultrastructural alterations of the Blood-Brain Barrier.
BACKGROUND: Widespread use of silver in its different forms raises concerns about potential adverse effects after ingestion, the main exposure route for humans. The aim of this study was to investigate in CD-1 (ICR) male mice the tissue distribution and in vivo effects of 4-week oral exposure to 0.25 and 1 mg Ag/kg bw 10 nm citrate coated silver nanoparticles (AgNPs) and 1 mg Ag/kg bw silver acetate (AgAc) at the end of treatment (EoT) and after 4 weeks of recovery. RESULTS: There were no treatment-related clinical signs and mortality, and no significant effects on body and organ weights at the EoT and after recovery. Treatment-related changes in hematology and clinical chemistry were found after recovery, the most relevant being a dose-dependent lymphopenia and increased triglycerides in AgNP-treated mice, and increased levels of urea in all treated groups, associated with decreased albumin only in AgAc-treated mice. At the EoT the highest silver concentration determined by Triple Quadrupole ICP-MS analysis was found in the brain, followed by testis, liver, and spleen; much lower concentrations were present in the small intestine and kidney. Tissue silver concentrations were slightly higher after exposure to AgAc than AgNPs and dose dependent for AgNPs. After recovery silver was still present in the brain and testis, highlighting slow elimination. No histopathological changes and absence of silver staining by autometallography were observed in the organs of treated mice. At the EoT GFAP (astrocytes) immunoreactivity was significantly increased in the hippocampus of AgNP-treated mice in a dose-dependent manner and Iba1 (microglial cells) immunoreactivity was significantly increased in the cortex of 1 mg/kg bw AgNP-treated mice. After recovery, a significant reduction of Iba1 was observed in the cortex of all treated groups. TEM analysis of the hippocampus revealed splitting of basement membrane of the capillaries and swelling of astrocytic perivascular end-feet in 1 mg/kg bw AgNP- and AgAc-treated mice at the EoT. CONCLUSIONS: Our study revealed accumulation and slow clearance of silver in the brain after oral administration of 10 nm AgNPs and AgAc at low doses in mice, associated with effects on glial cells and ultrastructural alterations of the Blood-Brain Barrier.
Authors: Helinor J Johnston; Gary Hutchison; Frans M Christensen; Sheona Peters; Steve Hankin; Vicki Stone Journal: Crit Rev Toxicol Date: 2010-04 Impact factor: 5.635
Authors: Agata P Walczak; Remco Fokkink; Ruud Peters; Peter Tromp; Zahira E Herrera Rivera; Ivonne M C M Rietjens; Peter J M Hendriksen; Hans Bouwmeester Journal: Nanotoxicology Date: 2012-10-01 Impact factor: 5.913
Authors: Jun Sung Kim; Eunye Kuk; Kyeong Nam Yu; Jong-Ho Kim; Sung Jin Park; Hu Jang Lee; So Hyun Kim; Young Kyung Park; Yong Ho Park; Cheol-Yong Hwang; Yong-Kwon Kim; Yoon-Sik Lee; Dae Hong Jeong; Myung-Haing Cho Journal: Nanomedicine Date: 2007-03 Impact factor: 5.307
Authors: Huong Huynh; Priya Upadhyay; Cora H Lopez; Malia K Miyashiro; Laura S Van Winkle; Sara M Thomasy; Kent E Pinkerton Journal: Toxicol Pathol Date: 2022-06-29 Impact factor: 1.930
Authors: Katarzyna Dziendzikowska; Jacek Wilczak; Wojciech Grodzicki; Joanna Gromadzka-Ostrowska; Małgorzata Węsierska; Marcin Kruszewski Journal: Int J Mol Sci Date: 2022-01-25 Impact factor: 5.923
Authors: Anna A Antsiferova; Marina Yu Kopaeva; Vyacheslav N Kochkin; Pavel K Kashkarov Journal: Nanomaterials (Basel) Date: 2021-11-26 Impact factor: 5.076